Antithrombin supplementation and mortality in sepsis-induced disseminated intravascular coagulation: A multicenter retrospective observational study

Shock

Volumn 46, Issue 6, 2016, Pages 623-631

  Hayakawa, Mineji ^a   Kudo, Daisuke ^b   Saito, Shinjiro ^c   Uchino, Shigehiko ^c   Yamakawa, Kazuma ^d   Iizuka, Yusuke ^e,f   Sanui, Masamitsu ^e   Takimoto, Kohei ^g   Mayumi, Toshihiko ^h   Ono, Kota ^a   Azuhata, Takeo ⁱ   Ito, Fumihito ^j   Yoshihiro, Shodai ^k   Hayakawa, Katsura ^l   Nakashima, Tsuyoshi ^m   Ogura, Takayuki ⁿ   Noda, Eiichiro ^o   Nakamura, Yoshihiko ^p   Sekine, Ryosuke ^q   Yoshikawa, Yoshiaki ^d   Sekino, Motohiro ^r   Ueno, Keiko ^s   Okuda, Yuko ^t   Watanabe, Masayuki ^u   Tampo, Akihito ^v   Saito, Nobuyuki ^w   Kitai, Yuya ^x   Takahashi, Hiroki ^g   Kobayashi, Iwao ^y   Kondo, Yutaka ^z   Matsunaga, Wataru ^e   Nachi, Sho ^aa   Miike, Toru ^ab   Takahashi, Hiroshi ^ac   Takauji, Shuhei ^ad   Umakoshi, Kensuke ^ae   Todaka, Takafumi ^af   Kodaira, Hiroshi ^ag   Andoh, Kohkichi ^ah   Kasai, Takehiko ^ai   Iwashita, Yoshiaki ^aj   Arai, Hideaki ^g   Murata, Masato ^ak   Yamane, Masahiro ^al   Shiga, Kazuhiro ^am   Hori, Naoto ^an   more..

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA GENERAL MEDICAL CENTER   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁱ NIHON UNIVERSITY   (Japan)

^j OHTA NISHINOUCHI HOSPITAL   (Japan)

^k JA Hiroshima General Hospital at Jigozen   (Japan)

^l SAITAMA RED CROSS HOSPITAL   (Japan)

^m WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁿ MAEBASHI RED CROSS HOSPITAL   (Japan)

^o KYUSHU UNIVERSITY HOSPITAL   (Japan)

^p FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^q IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^r NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^s TOKYO MEDICAL UNIVERSITY   (Japan)

^t KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^u SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^v ASAHIKAWA MEDICAL COLLEGE   (Japan)

^w NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^x KAMEDA MEDICAL CENTER   (Japan)

^y ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^z UNIVERSITY OF THE RYUKYUS   (Japan)

^aa GIFU UNIVERSITY HOSPITAL   (Japan)

^ab SAGA UNIVERSITY HOSPITAL   (Japan)

^ac Steel Memorial Muroran Hospital   (Japan)

^ad SAPPORO CITY GENERAL HOSPITAL   (Japan)

^ae EHIME UNIVERSITY HOSPITAL   (Japan)

^af Tomishiro Central Hospital   (Japan)

^ag Akashi City Hospital   (Japan)

^ah SENDAI CITY HOSPITAL   (Japan)

^ai Hakodate Municipal Hospital   (Japan)

^aj MIE UNIVERSITY HOSPITAL   (Japan)

^ak GUNMA UNIVERSITY   (Japan)

^al KKR Sapporo Medical Center   (Japan)

^am SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^an HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

Antithrombin; coagulation abnormality; disseminated intravascular coagulation; mortality; sepsis

Indexed keywords

ANTITHROMBIN; HEPARIN;

AGED; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SUPPLEMENTATION; SURVIVAL RATE; CLINICAL TRIAL; COMPLICATION; HOSPITAL MORTALITY; INTENSIVE CARE UNIT; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PROPENSITY SCORE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEPARIN; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; ODDS RATIO; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84983490309     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000727     Document Type: Article

References (34)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS,Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273(2):117-123, 1995.
2. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med 341(8):586-592, 1999.
3. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, et al.: Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey. Crit Care Med 36(1):145-150, 2008.
4. Levi M, van der Poll T: Inflammation and coagulation. Crit Care Med 38(2 suppl):S26-S34, 2010.
5. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF, et al.: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 8(2):R82-R90, 2004.
6. Gando S, Kameue T, Nanzaki S, Nakanishi Y: Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 75(2):224-228, 1996.
7. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101(3):816-823, 1992.
8. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286(15):1869-1878, 2001.
9. Afshari A, Wetterslev J, Brok J, Moller A: Antithrombin III in critically ill patients: Systematic review with meta-analysis and trial sequential analysis. BMJ 335(7632):1248-1251, 2007.
10. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580-637, 2013.
11. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM, et al.: High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety. Crit Care Med 34(2):285-292, 2006.
12. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R,Warren BL, Opal SM: KyberSept investigators. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 95(5):850-856, 2006.
13. Wiedermann CJ, Kaneider NC: A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 17(7):521-526, 2006.
14. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H: Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: An observational nationwide study. J Thromb Haemost 12(9):1470-1479, 2014.
15. Tagami T, Matsui H, Fushimi K, Yasunaga H: Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis. Thromb Haemost 114(3):537-545, 2015.
16. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, et al.: A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 17(6):R297, 2013.
17. Iba T, Saitoh D: Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. J Intensive Care 2(1):66, 2014.
18. Iba T, Saitoh D, Gando S, Thachil J: The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 135(5):897-901, 2015.
19. Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, Sanui M, Takimoto K, Mayumi T, Ono K, et al.: Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost 115(6): 1157-1166, 2016.
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit CareMed 31(4):1250-1256, 2003.
21. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T,Murata A, Ikeda T, Ishikura H, et al.: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit Care Med 34(3):625-631, 2006.
22. Austin PC: The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med 33(7):1242-1258, 2014.
23. Austin PC: A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27(12):2037-2049, 2008.
24. Ho D, Imai K, King G, SE A: Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal 15:199- 236, 2007.
25. Ho D, Imai K, King G, Stuart EA: MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 428:1-28, 2011.
26. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle CE, Levi M, et al.: Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 11:716-767, 2013.
27. Fourrier F: Severe sepsis, coagulation, and fibrinolysis: Dead end or one way? Crit Care Med 40(9):2704-2708, 2012.
28. Zhang Z, Ni H, Xu X: Observational studies using propensity score analysis underestimated the effect sizes in critical care medicine. J Clin Epidemiol 67(8):932-939, 2014.
29. Austin PC: The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32(16):2837-2849, 2013.
30. Wiedermann CJ: Clinical review: Molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 10(1):209, 2006.
31. Sakhuja A, Kumar G, Gupta S, Mittal T, Taneja A, Nanchal RS: Acute kidney injury requiring dialysis in severe sepsis. Am J Respir Crit Care Med 192(8):951-957, 2015.
32. Iba T, Saitoh D,Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A secondary survey. Crit Care 18(5):497, 2014.
33. Iba T, Saito D, Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. Thromb Res 130(3):e129-e133, 2012.
34. Hayakawa M, Gando S, Hoshino H: A prospective comparison of new Japanese criteria for disseminated intravascular coagulation: newJapanese criteria versus ISTH criteria. Clin Appl Thromb Hemost 13(2):172-181, 2007.